

methods for making said products are materially coupled and do not constitute distinct inventions within the meaning proscribed in MPEP § 806.05. Moreover, the close relationship of the subject matter of these groups clearly obviates the need for separate searching and examination by the Office, and coordinate examination of these groups would fulfill the Office's goal of compact prosecution while relieving Applicants of the burden that would attend strict application of the foregoing restriction requirement.

Applicant reserves the right to file a divisional or related application to the claims of non-elected group(s).

AMENDMENT

Please amend the application as follows:

In the Claims

Please cancel claim 95 without prejudice.

Please amend claim 100 as follows:

1 100. (Amended) The isolated infectious PIV particle of
2 claim 91, wherein the [counterpart gene or gene segment is a
3 gene or gene segment of the] recombinant PIV genome or
4 antigenome has one or more HPIV3 HN or F glycoprotein [gene
5 of] genes or gene segments substituted by one or more
6 counterpart HPIV1 or HPIV2 genes or gene segments.

Please add new claims 129-143 as follows:

1 --129. The isolated polynucleotide molecule of
2 claim 4, wherein the HN and F glycoprotein genes of HPIV1
3 are substituted for the counterpart HN and F glycoprotein
4 genes of HPIV3 to encode a chimeric genome or antigenome.

1 130. The isolated polynucleotide molecule of
2 claim 129, wherein the isolated polynucleotide encoding the
3 chimeric PIV genome or antigenome further incorporates one
4 or more mutations of JS cp45.

1
2
3
4
~~Sub 35~~
131. The isolated polynucleotide molecule of
claim 130, wherein said one or more mutations of JS cp45
comprise a plurality and up to a full complement of
mutations present in JS cp45.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
~~Sub 35~~
132. The isolated polynucleotide molecule of
claim 129, wherein the isolated polynucleotide encoding the
chimeric PIV genome or antigenome further incorporates a
full complement of mutations present in JS cp45, said full
complement of mutations comprising i) substitutions
specifying a replacement of His for Tyr₉₄₂, Phe for Leu₉₉₂,
and Ile for Thr₁₅₅₈ in the polymerase L protein; ii)
substitutions specifying a replacement of Ala for Val₉₆ and
Ala for Ser₃₈₉ in the N protein; iii) a substitution
specifying a replacement of Thre for Ile₉₆ in the C protein;
iv) substitution specifying an amino acid change in the F
protein comprising a replacement of Val for Ile₄₂₀ or Thr for
Ala₄₅₀; v) substitutions specifying a replacement of Ala for
Val₃₈₄ in the HN protein; vi) a substitution specifying a
replacement of Thr for Pro₁₉₉ in the M protein; vii)
mutations in a 3' leader sequence comprising a T to C change
at a position corresponding to nucleotide 23 of JS cp45, a C
to T change at nucleotide 24, a G to T change at nucleotide
28, and a T to A change at nucleotide 45 of JS cp45; and
viii) a mutation in an N gene start sequence comprising an A
to T change at a position corresponding to nucleotide 62 of
JS cp45.

1
2
3
4
~~Sub 35~~
133. The isolated polynucleotide molecule of
claim 36, wherein the HN and F glycoprotein genes of HPIV1
are substituted for the counterpart HN and F glycoprotein
genes of HPIV3.

1
2
3
4
~~Sub 35~~
134. The isolated polynucleotide molecule of
claim 133, wherein said chimeric genome or antigenome
incorporates a full complement of mutations present in JS

1 cp45, said full complement of mutations comprising i)
2 substitutions specifying a replacement of His for Tyr₉₄₂, Phe
3 for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the polymerase L protein;
4 ii) substitutions specifying a replacement of Ala for Val₉₆
5 and Ala for Ser₃₈₉ in the N protein; iii) a substitution
6 specifying a replacement of Thre for Ile₉₆ in the C protein;
7 iv) substitution specifying an amino acid change in the F
8 protein comprising a replacement of Val for Ile₄₂₀ or Thr for
9 Ala₄₅₀; v) substitutions specifying a replacement of Ala for
10 Val₃₈₄ in the HN protein; vi) a substitution specifying a
11 replacement of Thr for Pro₁₉₉ in the M protein; vii)
12 mutations in a 3' leader sequence comprising a T to C change
13 at a position corresponding to nucleotide 23 of JS cp45, a C
14 to T change at nucleotide 24, a G to T change at nucleotide
15 28, and a T to A change at nucleotide 45 of JS cp45; and
16 viii) a mutation in an N gene start sequence comprising an A
17 to T change at a position corresponding to nucleotide 62 of
18 JS cp45.

135. The method of claim 81, wherein the HN and F
2 glycoprotein genes of HPIV1 are substituted for the
3 counterpart HN and F glycoprotein genes of HPIV3.

136. The method of claim 135, wherein said genome
1 or antigenome incorporates a full complement of mutations
2 present in JS cp45, said full complement of mutations
3 comprising i) substitutions specifying a replacement of His
4 for Tyr₉₄₂, Phe for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the
5 polymerase L protein; ii) substitutions specifying a
6 replacement of Ala for Val₉₆ and Ala for Ser₃₈₉ in the N
7 protein; iii) a substitution specifying a replacement of
8 Thre for Ile₉₆ in the C protein; iv) substitution specifying
9 an amino acid change in the F protein comprising a
10 replacement of Val for Ile₄₂₀ or Thr for Ala₄₅₀; v)
11 substitutions specifying a replacement of Ala for Val₃₈₄ in
12 the HN protein; vi) a substitution specifying a replacement
13

Subj. B2
of Thr for Pro₁₉₉ in the M protein; vii) mutations in a 3' leader sequence comprising a T to C change at a position corresponding to nucleotide 23 of JS cp45, a C to T change at nucleotide 24, a G to T change at nucleotide 28, and a T to A change at nucleotide 45 of JS cp45; and viii) a mutation in an N gene start sequence comprising an A to T change at a position corresponding to nucleotide 62 of JS cp45.

1 2 3 4
137. The isolated infectious PIV particle of claim 97, wherein HN and F glycoprotein genes of HPIV1 are substituted for counterpart HN and F glycoprotein genes of HPIV3.

1 2 3 4
138. The isolated infectious PIV particle of claim 137, wherein the recombinant PIV genome or antigenome further incorporates one or more mutations of JS cp45.

1 2 3 4
139. The isolated infectious PIV particle of claim 138, wherein said one or more mutations of JS cp45 comprise a plurality and up to a full complement of mutations present in JS cp45.

1 2 3 4 5 6 7 8 9 10 11 12 13
140. The isolated infectious PIV particle of claim 137, wherein the isolated polynucleotide encoding the chimeric PIV genome or antigenome further incorporates a full complement of mutations present in JS cp45, said full complement of mutations comprising i) substitutions specifying a replacement of His for Tyr₉₄₂, Phe for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the polymerase L protein; ii) substitutions specifying a replacement of Ala for Val₉₆ and Ala for Ser₃₈₉ in the N protein; iii) a substitution specifying a replacement of Thre for Ile₉₆ in the C protein; iv) substitution specifying an amino acid change in the F protein comprising a replacement of Val for Ile₄₂₀ or Thr for Ala₄₅₀; v) substitutions specifying a replacement of Ala for

B3

1 Val₃₈₄ in the HN protein; vi) a substitution specifying a
2 replacement of Thr for Pro₁₉₉ in the M protein; vii)
3 mutations in a 3' leader sequence comprising a T to C change
4 at a position corresponding to nucleotide 23 of JS cp45, a C
5 to T change at nucleotide 24, a G to T change at nucleotide
6 28, and a T to A change at nucleotide 45 of JS cp45; and
7 viii) a mutation in an N gene start sequence comprising an A
8 to T change at a position corresponding to nucleotide 62 of
9 JS cp45.

10 141. The isolated infectious PIV particle of
11 claim 111, wherein said chimeric PIV genome or antigenome
12 further incorporates the full complement of mutations
13 present in JS cp45, said full complement of mutations
14 comprising i) substitutions specifying a replacement of His
15 for Tyr₉₄₂, Phe for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the
16 polymerase L protein; ii) substitutions specifying a
17 replacement of Ala for Val₉₆ and Ala for Ser₃₈₉ in the N
18 protein; iii) a substitution specifying a replacement of
19 Thre for Ile₉₆ in the C protein; iv) substitution specifying
20 an amino acid change in the F protein comprising a
21 replacement of Val for Ile₄₂₀ or Thr for Ala₄₅₀; v)
22 substitutions specifying a replacement of Ala for Val₃₈₄ in
the HN protein; vi) a substitution specifying a replacement
of Thr for Pro₁₉₉ in the M protein; vii) mutations in a 3'
leader sequence comprising a T to C change at a position
corresponding to nucleotide 23 of JS cp45, a C to T change
at nucleotide 24, a G to T change at nucleotide 28, and a T
to A change at nucleotide 45 of JS cp45; and viii) a
mutation in an N gene start sequence comprising an A to T
change at a position corresponding to nucleotide 62 of JS
cp45.

1 142. The immunogenic composition of claim 124,
2 wherein the HN and F glycoprotein genes of HPIV1 are